Pharma Foods International Co., Ltd.
Notice on impairment loss recognition for a related company’s shares (individual financial statements)
In the individual financial results for the fiscal year ending July 2026, impairment processing of the equity interests in Onkyo Corporation accounted for using the equity method was conducted. Impairment losses on related company equity securities are expected to be 422 million yen, with no impact on the consolidated results. As part of impairment of goodwill, an investment loss of 171 million yen is expected to be recognized as an extraordinary loss. The impact on earnings is referenced in the full-year earnings guidance update disclosed separately.
Key Figures
- Related company equity securities impairment: 422 million yen
- Investment loss due to impairment of goodwill: 171 million yen
- Impact on 2026 fiscal year results: No impact on consolidated results (refer to disclosure)
AI要約
Section Heading
This notice announces the recognition of extraordinary losses in the individual financial statements for the fiscal year ending July 2026. In response to a substantial drop in the carrying amount of related company equity securities, impairment is being recognized for Onkyo Corporation shares. Accordingly, related company equity securities impairment is expected to be recorded as an extraordinary loss of 422 million yen. The impact on the consolidated results will be offset, but impairment of Onkyo’s goodwill will also be recognized, with an investment loss of 171 million yen recorded as an extraordinary loss.
Section 2
For the impact on the 2026 fiscal year’s performance, please refer to the separately disclosed note “Revision of Full-Year Earnings Guidance for the Fiscal Year Ending July 2026.” The IR contact point is clearly stated, and a framework for providing additional information is in place.
Pharma Foods International Co., Ltd.
Company overview · Stock price · Financial data · All IR
